Insulet Corporation $PODD Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd trimmed its position in Insulet Corporation (NASDAQ:PODD) by 42.6% during the 3rd quarter, Holdings Channel.com reports. The fund owned 13,238 shares of the medical instruments supplier’s stock after selling 9,830 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Insulet were worth $4,087,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of PODD. Sage Mountain Advisors LLC raised its holdings in shares of Insulet by 4.6% in the third quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier’s stock valued at $229,000 after buying an additional 33 shares during the last quarter. Curi Capital LLC grew its holdings in shares of Insulet by 0.8% in the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after acquiring an additional 36 shares during the period. Evelyn Partners Investment Management Services Ltd raised its stake in shares of Insulet by 28.7% during the 2nd quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock worth $55,000 after buying an additional 39 shares during the last quarter. PDS Planning Inc lifted its holdings in shares of Insulet by 5.1% in the third quarter. PDS Planning Inc now owns 821 shares of the medical instruments supplier’s stock valued at $253,000 after purchasing an additional 40 shares in the last quarter. Finally, Camarda Financial Advisors LLC grew its holdings in Insulet by 0.5% during the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after buying an additional 40 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. TD Cowen reiterated a “buy” rating on shares of Insulet in a research report on Thursday, December 4th. Truist Financial dropped their price target on shares of Insulet from $412.00 to $390.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Wells Fargo & Company increased their price target on shares of Insulet from $350.00 to $360.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. UBS Group reaffirmed a “buy” rating on shares of Insulet in a research report on Thursday, December 18th. Finally, Raymond James Financial boosted their price target on Insulet from $366.00 to $385.00 and gave the company an “outperform” rating in a research report on Friday, November 21st. Twenty-one research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $379.10.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $271.57 on Monday. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.68. The firm has a 50-day simple moving average of $298.48 and a 200 day simple moving average of $310.34. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $354.88. The company has a market cap of $19.10 billion, a PE ratio of 78.72, a P/E/G ratio of 1.51 and a beta of 1.40.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The business had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The business’s quarterly revenue was up 29.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.08 EPS. On average, sell-side analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.